{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:59:38Z","timestamp":1785765578022,"version":"3.56.0"},"reference-count":48,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/na","name":"Von Pfeffel Pharmaceuticals","doi-asserted-by":"publisher","award":["D\/108-22563"],"award-info":[{"award-number":["D\/108-22563"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Liposomal nanomedicines offer a clinically proven platform for enhanced drug delivery, yet their behavior in vivo remains difficult to characterize. Noninvasive positron emission tomography (PET) imaging with radiolabeled liposomes enables quantitative insight into their biodistribution and pharmacokinetics, supporting the rational design and clinical translation of nanocarrier-based therapeutics. Zirconium-89 ([89Zr]Zr) is a positron emitter with a suitable half-life (t1\/2 = 78.4 h) for tracking long-circulating nanocarriers such as PEGylated liposomes by PET imaging. However, existing manual labeling protocols often suffer from poor reproducibility, drug leakage, and limited scalability for clinical translation. Automated radiolabeling and purification of macromolecular systems, such as liposomes, antibodies, and antibody fragments, are essential for the reproducible, clinically translatable production of radiopharmaceuticals. However, these requirements necessitate larger and more complex radiosynthesizers that are often not suitable for smaller laboratories. Although automated procedures using complex synthesis modules with integrated high-performance liquid chromatography purification have been demonstrated on larger radiosynthesizers, comparable processes on simpler synthesis platforms remain scarce. To address this gap, this study aimed to develop a fully automated process for the 89Zr-radiolabeling and subsequent size-exclusion chromatography (SEC) purification of doxorubicin-loaded, PEGylated liposomes using the ML Eazy synthesis platform. The process was designed in a GMP-oriented manner with the goal of enabling its future application to other macromolecular radiopharmaceuticals. Using this approach, a fully automated procedure was successfully established on the ML Eazy platform, although optimization of a published labeling method was required to eliminate doxorubicin leakage and improve radiolabeling efficiency. Several system configurations were tested to optimize SEC and sterile filtration, resulting in a robust setup that enabled efficient purification and reproducible performance. Fine-tuning of reagent transfer, gradual pressure increase, and intermediate saline rinsing with subsequent air flushing reduced residual activity in tubing and connectors to &amp;lt;5%. The final automated process achieved consistent radiochemical yields of 67 \u00b1 3% across eight batches prepared under GMP-oriented conditions. Overall, an automated, GMP-oriented all-in-one procedure for 89Zr-labeling with subsequent size-exclusion purification of liposomes has been successfully established, producing sterile-filtered formulations that support future clinical translation. The automated module may also be adapted for other radiolabeling applications using SEC, including antibody labeling.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00129","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:40:31Z","timestamp":1782726031000},"page":"4112-4122","source":"Crossref","is-referenced-by-count":0,"title":["Done EAZY:\nAn Automated Procedure for 89Zr-Radiolabeling and Size-Exclusion\nChromatography Purification of\nNanoliposomal Anticancer Therapeutics"],"prefix":"10.1021","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6091-044X","authenticated-orcid":true,"given":"Justin","family":"Dubbert","sequence":"first","affiliation":[{"name":"University Duisburg-Essen and DKTK-partner Site University Hospital Essen , , ,","place":["Essen, Germany, 45147"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Kunkel","sequence":"additional","affiliation":[{"name":"Eckert & Ziegler Eurotope GmbH , ,","place":["Berlin, Germany, 13125"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mu\u0308hlenberg","sequence":"additional","affiliation":[{"name":"West German Cancer Center , , ,","place":["Essen, Germany, 45147"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Grunewald","sequence":"additional","affiliation":[{"name":"West German Cancer Center , , ,","place":["Essen, Germany, 45147"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[{"name":"University Duisburg-Essen and DKTK-partner Site University Hospital Essen , , ,","place":["Essen, Germany, 45147"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[{"name":"West German Cancer Center , , ,","place":["Essen, Germany, 45147"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6109-2066","authenticated-orcid":true,"given":"Katharina","family":"Lu\u0308ckerath","sequence":"additional","affiliation":[{"name":"University Duisburg-Essen and DKTK-partner Site University Hospital Essen , , ,","place":["Essen, Germany, 45147"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2095-9641","authenticated-orcid":true,"given":"Valeska","family":"von Kiedrowski","sequence":"additional","affiliation":[{"name":"University Duisburg-Essen and DKTK-partner Site University Hospital Essen , , ,","place":["Essen, Germany, 45147"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"1","key":"2026080309072904100_cit1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/acs.nanolett.0c04638","article-title":"Keeping nanomedicine on target","volume":"21","author":"Zhang","year":"2020","journal-title":"Nano Lett."},{"issue":"2","key":"2026080309072904100_cit2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\n- The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Controlled Release"},{"issue":"2\u20133","key":"2026080309072904100_cit3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/s0169-409x(96)00453-x","article-title":"The design\nand development of DaunoXome\u00ae for solid tumor targeting in vivo","volume":"24","author":"Forssen","year":"1997","journal-title":"Adv. Drug Delivery Rev."},{"issue":"3","key":"2026080309072904100_cit4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae(vincristine sulfate\nliposome injection)\nimproves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2026080309072904100_cit5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1021\/bc100070g","article-title":"Tumor-selective\ndelivery of macromolecular drugs via the EPR effect: background and\nfuture prospects","volume":"21","author":"Maeda","year":"2010","journal-title":"Bioconjug Chem."},{"issue":"3","key":"2026080309072904100_cit6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery\nof macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv. Drug Delivery Rev."},{"issue":"12","key":"2026080309072904100_cit7","first-page":"6387","article-title":"A new concept for macromolecular\ntherapeutics in cancer chemotherapy:\nmechanism of tumoritropic accumulation of proteins and the antitumor\nagent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"issue":"1","key":"2026080309072904100_cit8","first-page":"83","article-title":"Phase\nI clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)\nmethacrylamide copolymer doxorubicin]: first member of a new class\nof chemotherapeutic agents - drug-polymer conjugates","volume":"5","author":"Vasey","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"2026080309072904100_cit9","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.2147\/ijn.s146315","article-title":"Effective use of nanocarriers as\ndrug delivery systems for the treatment of selected tumors","volume":"12","author":"Din","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"2026080309072904100_cit10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","article-title":"Toward a full\nunderstanding of the EPR effect in primary and metastatic tumors as\nwell as issues related to its heterogeneity","volume":"91","author":"Maeda","year":"2015","journal-title":"Adv. Drug Delivery Rev."},{"issue":"3","key":"2026080309072904100_cit11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/jpm13030389","article-title":"Approaches to Improve EPR-Based Drug\nDelivery for Cancer\nTherapy and Diagnosis","volume":"13","author":"Subhan","year":"2023","journal-title":"J. Pers. Med."},{"issue":"18","key":"2026080309072904100_cit12","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1158\/1078-0432.CCR-12-1414","article-title":"Personalized\nnanomedicine","volume":"18","author":"Lammers","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"2026080309072904100_cit13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1021\/tx2005212","article-title":"Use of radiolabeled\ncompounds in drug metabolism and pharmacokinetic studies","volume":"25","author":"Isin","year":"2012","journal-title":"Chem. Res. Toxicol."},{"issue":"5","key":"2026080309072904100_cit14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s11307-018-1255-2","article-title":"Imaging Nanomedicine-Based Drug Delivery:\na Review of Clinical Studies","volume":"20","author":"Man","year":"2018","journal-title":"Mol. Imaging Biol."},{"key":"2026080309072904100_cit15","unstructured":"Trasis.\n          . Trasis Tracer [89Zr] and\n[225Ac] mAb Page. https:\/\/www.trasis.com\/en\/product\/89zr-and-225acmab\/. Accessed: April 14, 2026."},{"key":"2026080309072904100_cit16","doi-asserted-by":"publisher","first-page":"108351","DOI":"10.1016\/j.nucmedbio.2023.108351","article-title":"Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab\nfor imaging of PD-L1 expressing tumours in vivo","volume":"120\u2013121","author":"Wichmann","year":"2023","journal-title":"Nucl. Med. Biol."},{"issue":"11","key":"2026080309072904100_cit17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056708","article-title":"ImmunoPET:\nIMaging of cancer imMUNOtherapy\ntargets with positron Emission Tomography: a phase 0\/1 study characterising\nPD-L1 with 89Zr-durvalumab (MEDI4736) PET\/CT in stage III NSCLC patients\nreceiving chemoradiation study protocol","volume":"12","author":"Hegi-Johnson","year":"2022","journal-title":"BMJ.\nOpen"},{"issue":"3","key":"2026080309072904100_cit18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ijrobp.2023.05.019","article-title":"PD-L1 Positron Emission Tomography\nImaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results\nof the ImmunoPET Phase 0 Study","volume":"117","author":"Hegi-Johnson","year":"2023","journal-title":"Int. J. Radiat.\nOncol., Biol., Phys."},{"key":"2026080309072904100_cit19","doi-asserted-by":"publisher","first-page":"112051","DOI":"10.1016\/j.apradiso.2025.112051","article-title":"Automated zirconium-89 and lutetium-177 antibody labeling\nand formulation using a Trasis MiniAIO module","volume":"225","author":"van der Wildt","year":"2025","journal-title":"Appl. Radiat. Isot."},{"key":"2026080309072904100_cit20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0076-6879(03)73015-8","article-title":"Radiolabeling\nof liposomes for scintigraphic\nimaging","volume":"373","author":"Laverman","year":"2003","journal-title":"Methods Enzymol."},{"issue":"1","key":"2026080309072904100_cit21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/wnan.3","article-title":"Radioactive liposomes","volume":"1","author":"Phillips","year":"2009","journal-title":"Wiley Interdiscip. Rev.:Nanomed. Nanobiotechnol."},{"issue":"5","key":"2026080309072904100_cit22","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3390\/pharmaceutics15051426","article-title":"Radiolabelled extracellular\nvesicles as imaging modalities for precise\ntargeted drug delivery","volume":"15","author":"Ashique","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"2026080309072904100_cit23","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/17425247.2016.1205584","article-title":"Radionuclide imaging of liposomal\ndrug delivery","volume":"13","author":"Van der Geest","year":"2016","journal-title":"Expert Opin. Drug Delivery"},{"issue":"41","key":"2026080309072904100_cit24","doi-asserted-by":"publisher","first-page":"22796","DOI":"10.1021\/acsami.5b04612","article-title":"Remote loading of 64Cu2+ into liposomes\nwithout the use of ion transport enhancers","volume":"7","author":"Henriksen","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"18","key":"2026080309072904100_cit25","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1073\/pnas.85.18.6949","article-title":"Liposome formulations with prolonged circulation time\nin blood and enhanced uptake by tumors","volume":"85","author":"Gabizon","year":"1988","journal-title":"Proc.\nNatl. Acad. Sci. U. S. A."},{"key":"2026080309072904100_cit26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jconrel.2015.10.043","article-title":"Comparison of three\nremote radiolabelling methods for long-circulating liposomes","volume":"220","author":"Van Der Geest","year":"2015","journal-title":"J. Controlled Release"},{"issue":"45","key":"2026080309072904100_cit27","doi-asserted-by":"publisher","first-page":"16451","DOI":"10.1039\/D1DT02685B","article-title":"Inorganic radiopharmaceutical\nchemistry of oxine","volume":"50","author":"Southcott","year":"2021","journal-title":"Dalton Trans."},{"issue":"2","key":"2026080309072904100_cit28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0891-8422(23)00150-7","article-title":"Clinical imaging\nwith indium 111 oxine-labeled leukocyte\nscan: review and case report","volume":"5","author":"Simon","year":"1988","journal-title":"Clin. Podiatr.\nMed. Surg."},{"issue":"4","key":"2026080309072904100_cit29","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00259-010-1393-5","article-title":"Guidelines\nfor the labelling of leucocytes with 111In-oxine","volume":"37","author":"Roca","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"2026080309072904100_cit30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.nucmedbio.2009.03.001","article-title":"In vitro\nhuman leukocyte\nlabeling with 64Cu: an intraindividual comparison with 111In-oxine\nand 18F-FDG","volume":"36","author":"Bhargava","year":"2009","journal-title":"Nucl. Med. Biol."},{"issue":"2","key":"2026080309072904100_cit31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1148\/radiol.15142849","article-title":"89Zr-oxine complex\nPET cell imaging in monitoring cell-based\ntherapies","volume":"275","author":"Sato","year":"2015","journal-title":"Radiology"},{"issue":"2","key":"2026080309072904100_cit32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00259-014-2945-x","article-title":"[89Zr] oxinate4 for long-term in\nvivo cell tracking\nby positron emission tomography","volume":"42","author":"Charoenphun","year":"2015","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"issue":"1","key":"2026080309072904100_cit33","first-page":"67","article-title":"68Ga [Ga]-,\n111In [In]-oxine: A novel strategy of in situ radiolabeling of HPMA-based\nmicelles","volume":"9","author":"de la Fuente","year":"2019","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"11","key":"2026080309072904100_cit34","doi-asserted-by":"publisher","first-page":"10294","DOI":"10.1021\/acsnano.6b05935","article-title":"Exploiting\nthe metal-chelating properties of the drug cargo for in vivo positron\nemission tomography imaging of liposomal nanomedicines","volume":"10","author":"Edmonds","year":"2016","journal-title":"ACS Nano"},{"issue":"9","key":"2026080309072904100_cit35","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.7150\/thno.40403","article-title":"PET\nimaging of liposomal glucocorticoids using 89Zr-oxine: theranostic\napplications in inflammatory arthritis","volume":"10","author":"Gawne","year":"2020","journal-title":"Theranostics"},{"key":"2026080309072904100_cit36","doi-asserted-by":"publisher","first-page":"bioRxiv:2025.06.17.660144","DOI":"10.1101\/2025.06.17.660144","article-title":"A translatable\nevaluation tool to study the biodistribution of clinically-available\ndoxorubicin liposomes: PET imaging of [89Zr]Zr-Doxil and [89Zr]Zr-Talidox","author":"Carrascal-Minin\u0303o","year":"2025","journal-title":"bioRxiv"},{"key":"2026080309072904100_cit37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.nucmedbio.2020.09.002","article-title":"A kit formulation for the preparation of [89Zr] Zr\n(oxinate) 4 for PET cell tracking: White blood cell labelling and\ncomparison with [111In] In (oxinate) 3","volume":"90\u201391","author":"Man","year":"2020","journal-title":"Nucl.\nMed. Biol."},{"issue":"39","key":"2026080309072904100_cit38","doi-asserted-by":"publisher","first-page":"14851","DOI":"10.1039\/C4DT01928H","article-title":"Synthesis\nand characterisation of zirconium complexes\nfor cell tracking with Zr-89 by positron emission tomography","volume":"43","author":"Ferris","year":"2014","journal-title":"Dalton Trans."},{"issue":"1","key":"2026080309072904100_cit39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical\napplications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Delivery Rev."},{"issue":"5","key":"2026080309072904100_cit40","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2967\/jnumed.118.217158","article-title":"Fully automated\n89Zr labeling and purification of antibodies","volume":"60","author":"Poot","year":"2019","journal-title":"J. Nucl. Med."},{"key":"2026080309072904100_cit41","doi-asserted-by":"publisher","first-page":"1566257","DOI":"10.3389\/fphar.2025.1566257","article-title":"Automated fluorine-18\nradiolabeling via an\nalkyne\u2013azide cycloaddition reaction on a dual peptide-functionalized\nliposome surface for in vivo PET imaging","volume":"16","author":"Iannone","year":"2025","journal-title":"Front.\nPharmacol."},{"key":"2026080309072904100_cit42","unstructured":"Eckert & Ziegler.\n          .  Eckert & Ziegler\nModular-Lab Eazy\u2500Radiosynthesizer. https:\/\/medical.ezag.com\/en\/products\/modular-lab-eazy\/. Accessed:\nApril 14, 2026."},{"issue":"2","key":"2026080309072904100_cit43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/14737140.2.2.143","article-title":"Caelyx\/Doxil for the\ntreatment of metastatic ovarian and breast cancer","volume":"2","author":"Tejada-Berges","year":"2002","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"6","key":"2026080309072904100_cit44","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/ph16060802","article-title":"Recent advances in doxorubicin formulation\nto enhance pharmacokinetics and tumor targeting","volume":"16","author":"Lee","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2026080309072904100_cit45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0005-2736(88)90234-9","article-title":"Surfactant-induced release of liposomal\ncontents. A survey of methods and results","volume":"937","author":"Ruiz","year":"1988","journal-title":"Biochim.\nBiophys. Acta Biomembr."},{"issue":"2","key":"2026080309072904100_cit46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0378-5173(99)00105-2","article-title":"Surfactant-induced\nleakage from liposomes:\na comparison among different lecithin vesicles","volume":"184","author":"Memoli","year":"1999","journal-title":"Int. J. Pharm."},{"issue":"3","key":"2026080309072904100_cit47","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4314\/tjpr.v10i3.1","article-title":"Penetration\nenhancing effect of polysorbate 20 and 80 on the in vitro percutaneous\nabsorption of lascorbic acid","volume":"10","author":"Naveed","year":"2011","journal-title":"Trop. J. Pharm.\nRes."},{"issue":"6","key":"2026080309072904100_cit48","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/jps.23969","article-title":"Modifying the release\nproperties of liposomes toward\npersonalized medicine","volume":"103","author":"Cipolla","year":"2014","journal-title":"J. Pharmaceut. Sci."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00129","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4112\/65268164\/acs.molpharmaceut.6c00129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/8\/4112\/65268164\/acs.molpharmaceut.6c00129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:13:47Z","timestamp":1785762827000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/8\/4112\/5170126\/Done-EAZY-An-Automated-Procedure-for-89Zr"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,6,29]]},"published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00129","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}